Skip to main content

Table 3 Laboratory findings before and after ezetimibe monotherapy and combined therapy

From: Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia

  Monotherapy (n = 71) Combined therapy (n = 20)
Parameters Pre Post 6M Pre Post 6M
Body mass index (kg/m2) 28.2 ± 3.7 28.0 ± 3.8 27.2 ± 2.0 25.9 ± 1.6*
Waist circumference (cm) 94.6 ± 8.2 92.8 ± 8.6*** 91.0 ± 5.6 88.3 ± 5.3**
Systolic blood pressure (mmHg) 130.1 ± 14.6 128.8 ± 13.2* 125.6 ± 13.8 121.8 ± 11.2
Diastolic blood pressure (mmHg) 77.3 ± 9.5 75.9 ± 10.6* 71.7 ± 8.2 69.5 ± 7.7
Total cholesterol (mg/dl) 237.9 ± 35.9 212.0 ± 33.0*** 224.7 ± 27.8 192.2 ± 36.1*
LDL-cholesterol (mg/dl) 151.3 ± 28.6 132.4 ± 28.6*** 132.1 ± 26.8 107.8 ± 30.5*
HDL-cholesterol (mg/dl) 51.9 ± 9.9 55.1 ± 9.4*** 50.8 ± 11.9 53.3 ± 11.5***
Non HDL-cholesterol (mg/dl) 184.9 ± 31.7 155.6 ± 32.5*** 174.6 ± 25.8 141.8 ± 32.2**
Triglycerides+ (mg/dl) 157.5 129.2*** 210.9 155.3***
RLP-cholesterol+ (mg/dl) 6.3 4.7** 8.2 4.7***
Free fatty acid+ (mEq/l) 435.9 505.6* 435.4 429.7
Plasma glucose (mg/dl) 105.1 ± 27.9 102.6 ± 26.4* 109.3 ± 21.7 105.1 ± 15.9
Insulin+ (μU/ml) 12.1 9.6** 11.7 11.4
HOMA index+ 3.0 2.4** 3.2 2.9
hsCRP+ (mg/dl) 807.0 883.7* 686.1 879.6*
Aldosterone (pg/dl)+ 86.9 92.9* 101.6 110.8
HGF (ng/ml) 0.33 ± 0.07 0.31 ± 0.04* 0.31 ± 0.03 0.30 ± 0.02
Adiponectine (μg/ ml)+ 2.51 2.56 2.49 2.47
EPA/AA+ 0.29 0.28 0.39 0.40
  1. *: p < 0.05, **: p < 0.01, ***: p < 0.001.
  2. Data are means (SD), geometric mean and range. *: These variables are shown in the original scale after analysis using log (natural)-transformed values.
  3. Abbreviations: RLP Remnant-like particle cholesterol, HOMA Homeostasis model assessment, HGF Hepatocyte growth factor, EPA/AA Eicosapentaenoic acid to arachidonic acid.